Voyager Therapeutics (VYGR) Financial Statements & Analysis

Voyager Therapeutics (VYGR) Income Statement

Voyager Therapeutics reported revenue of $40.37M in fiscal 2025 (fiscal year ended Dec 31, 2025), down 49.5% from $80.00M a year earlier. Voyager Therapeutics posted a net loss of $119.72M, compared with a net loss of $65.00M a year earlier. Gross margin was -227.6% and operating margin -326.6%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $3.17M, down 39.1% from the same quarter a year earlier.

Voyager Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Voyager Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	40.37	80.00	250.01	40.91	37.42	171.13	104.39	7.62	10.14
Cost of Revenue	132.27	124.59	92.17	55.76	73.79	108.75	119.74	64.91	62.26
Gross Profit	-91.90	80.00	157.84	-14.86	37.42	62.38	-15.34	-57.29	-52.13
Operating Expenses
Research & Development	134.67	127.37	92.17	60.76	73.79	108.75	119.74	64.91	62.26
Selling, General & Administrative	36.44	35.92	35.82	30.98	37.25	34.99	36.34	33.81	19.74
Operating Expenses	39.94	163.29	127.99	35.98	111.03	34.99	36.34	98.71	82.00
Operating Income	-131.84	-83.29	122.01	-50.84	-73.62	27.38	-51.68	-91.10	-71.86
Other Income/Expense
Interest Income	10.62	18.33	11.72	1.79	-0.39	1.66	6.46	3.31	1.23
Interest Expense	0.00	0.00	0.00	0.00	-0.39	0.00	0.00	0.00	0.00
Other Income/Expense	12.27	18.95	0.00	4.45	2.42	9.36	8.08	2.63	1.17
Income
Income Before Tax	-119.58	-64.34	133.74	-46.39	-71.20	36.74	-43.60	-88.47	-70.70
Income Tax Expense	0.14	0.67	1.41	0.02	0.00	0.00	0.00	-0.18	0.00
Net Income	-119.72	-65.00	132.33	-46.41	-71.20	36.74	-43.60	-88.29	-70.70
Net Income - Continuous Operations	-119.72	-65.00	132.33	-46.41	-71.20	36.74	-43.60	-88.29	-70.70
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	-115.52	-75.78	126.46	-39.65	-68.45	31.20	-48.91	-88.98	-70.27
EBIT	-131.84	-80.51	122.01	-50.84	-73.62	27.38	-	-	-
Depreciation & Amortization	4.06	4.73	4.44	6.19	5.17	3.82	2.77	2.12	1.60
Earnings Per Share
Basic EPS	-2.00	-1.00	3.00	-1.00	-2.00	1.00	-1.00	-3.00	-3.00
Diluted EPS	-2.00	-1.00	3.00	-1.00	-2.00	1.00	-1.00	-3.00	-3.00
Basic Shares Outstanding	58.69	57.67	43.02	38.36	37.67	37.13	35.90	32.07	26.80
Diluted Shares Outstanding	58.69	57.67	44.57	38.36	37.67	37.35	35.90	32.07	26.80

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Voyager Therapeutics Financial Statements

What was Voyager Therapeutics's revenue in fiscal 2025?

Voyager Therapeutics reported revenue of $40.37M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 49.5% from $80.00M a year earlier.

Is Voyager Therapeutics profitable?

No. Voyager Therapeutics reported a net loss of $119.72M in fiscal 2025. In fiscal 2024 it lost $65.00M.

What is Voyager Therapeutics's operating margin?

Voyager Therapeutics's operating income was −$131.84M on revenue of $40.37M in fiscal 2025, an operating margin of -326.6%, compared with -104.1% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition